How should an 18‑year‑old woman on fluoxetine with suspected drug‑induced hypersensitivity reaction with hepatic involvement (DRESS) presenting with eyelid swelling be managed?

Management of DRESS Syndrome with Eyelid Swelling in an 18-Year-Old on Fluoxetine

Immediately discontinue fluoxetine and consult ophthalmology urgently, as eyelid swelling in DRESS syndrome indicates potential mucous membrane involvement that requires specialized evaluation to prevent permanent ocular sequelae. 1

Immediate Actions

Discontinue the offending drug immediately - fluoxetine must be stopped without delay, as continued exposure worsens outcomes in DRESS syndrome. 1, 2 While fluoxetine is rarely reported as a DRESS culprit compared to anticonvulsants and sulfonamides, case reports confirm it can cause severe hypersensitivity reactions including DRESS in young patients. 3, 4

Consult ophthalmology emergently - eyelid swelling represents potential mucous membrane involvement, which can lead to permanent scarring and visual complications if not managed appropriately. 1 The ASCO guidelines specifically recommend ophthalmology consultation for mucous membrane involvement in drug hypersensitivity syndromes to prevent sequelae from scarring. 1

Severity Assessment and Hospitalization Decision

Admit the patient for inpatient management given the presence of hepatic involvement combined with eyelid swelling. 1 The combination of systemic organ involvement (liver) with potential mucous membrane manifestations warrants intensive monitoring. 1

Key severity indicators to assess:

• Extent of hepatic dysfunction - check transaminases, bilirubin, INR, and synthetic function 4, 5, 6
• Degree of eosinophilia - peripheral eosinophil count correlates with cardiac involvement risk 5
• Presence of fever - typically moderate to high grade (>38°C) in DRESS 6
• Facial edema extent - beyond just eyelids suggests more severe systemic involvement 7
• Other organ involvement - assess renal function, cardiac markers (troponin for myocarditis), and lymphadenopathy 4, 5, 7

Pharmacologic Management

Initiate IV methylprednisolone 0.5-1 mg/kg daily for DRESS with hepatic involvement and convert to oral corticosteroids upon response, tapering over at least 4 weeks. 1 The ASCO guidelines emphasize that adequate immunosuppression is necessary and may be prolonged in DRESS cases. 1

For this 18-year-old patient, systemic corticosteroids remain the mainstay treatment for DRESS with internal organ involvement. 7 The typical approach:

• Start with IV methylprednisolone 40-60 mg daily (assuming ~60-80 kg body weight) 6
• Monitor clinical response closely - improvement in fever, rash, and liver enzymes typically occurs within days 6
• Transition to oral prednisone once stable, maintaining 0.5-1 mg/kg equivalent 7
• Taper very slowly over 6-12 weeks - rapid taper risks relapse, which occurs in 20-30% of DRESS cases 7

Consider IVIG or cyclosporine if steroid-unresponsive or severe presentation. 1 Steroid-sparing agents including cyclosporine and mycophenolate mofetil have been successfully used. 7

Supportive Care and Monitoring

Topical management:

• High-strength topical corticosteroids for skin lesions 1
• Petrolatum-based emollients for skin barrier protection 1
• Oral antihistamines for symptomatic relief 1

Laboratory monitoring:

• Daily initially: CBC with differential (eosinophils, atypical lymphocytes), comprehensive metabolic panel, liver function tests 4, 5
• Cardiac monitoring: Troponin and ECG - myocarditis is a leading cause of DRESS mortality and often unrecognized 7
• Viral reactivation screening: Consider HHV-6, EBV, CMV testing as reactivation occurs in 2-4 weeks and can complicate management 7

Critical Pitfalls to Avoid

Do not rechallenge with fluoxetine - the FDA label warns that severe skin reactions including Stevens-Johnson syndrome can occur with SSRIs, and rechallenge can lead to serious or fatal reactions. 2 Permanent discontinuation is mandatory. 1

Avoid all structurally related SSRIs - cross-reactivity may occur with other selective serotonin reuptake inhibitors. 7 Future antidepressant selection should involve different drug classes if needed.

Monitor for late complications:

• Autoimmune sequelae - thyroiditis and other autoimmune diseases can develop months after DRESS resolution 7, 8
• CMV reactivation - occurs 2-4 weeks post-onset and contributes significantly to morbidity/mortality 7
• Relapse - occurs in 20-30% of cases, often coinciding with viral reactivation or premature steroid taper 7

Do not miss cardiac involvement - unrecognized myocarditis is a leading cause of DRESS mortality (up to 10% overall mortality). 7 Serial troponins and ECGs are essential even without cardiac symptoms.

Ophthalmologic Considerations

The ophthalmology team should evaluate for:

• Conjunctival involvement - can progress to scarring and symblepharon 9
• Corneal epithelial defects - require aggressive lubrication 9
• Anterior uveitis - may necessitate topical corticosteroids 9
• Eyelid margin involvement - can lead to chronic blepharitis 9

Early ophthalmologic intervention prevents long-term visual complications that can occur with mucous membrane involvement in severe drug hypersensitivity reactions. 1

Fluoxetine-Specific Considerations

The long half-life of fluoxetine (4-6 days) and its active metabolite norfluoxetine (4-16 days) means active drug will persist for weeks after discontinuation. 2 This prolonged elimination may extend the duration of hypersensitivity manifestations and requires extended monitoring even after drug cessation. 2

Given fluoxetine's hepatic metabolism, the already compromised liver function in this DRESS case may further prolong drug clearance. 2 This pharmacokinetic consideration supports aggressive early immunosuppression rather than waiting for drug elimination alone.